---
import ScienceLayout from '../../layouts/ScienceLayout.astro';
import { Image } from 'astro:assets';

import rodriguesGA from '../../assets/images/science/rodrigues-2024-graphical-abstract.jpg';
import rodriguesFig3 from '../../assets/images/science/rodrigues-2024-fig3.jpg';
import mannaFig2 from '../../assets/images/science/manna-2021-fig2.jpg';
import mannaFig4 from '../../assets/images/science/manna-2021-fig4.jpg';
import gaszekFig1 from '../../assets/images/science/gaszek-2025-fig1.jpg';
import gaszekFig2 from '../../assets/images/science/gaszek-2025-fig2.jpg';
import lyonFig1 from '../../assets/images/science/lyon-2025-fig1.jpg';
import lyonFig3 from '../../assets/images/science/lyon-2025-fig3.jpg';
---

<ScienceLayout title="Antibiotic Resistance Evolution | Toprak Lab" description="Understanding how bacteria evolve resistance through protein epistasis, large-scale mutagenesis, and evolutionary dynamics.">
  <section class="section">
    <div class="container">
      <p class="vision-intro">
        Antibiotic resistance is evolution in a hurry — and it rarely hinges on a single trick. Pathogens can survive by hiding in the host, by taking a few key mutational steps, or by exploring an enormous combinatorial space of enzyme variants. Our goal is to make that search process measurable, so we can predict the paths most likely to appear and design drugs and treatment strategies that close them.
      </p>
    </div>
  </section>

  <section class="section section--alt">
    <div class="container">
      <h2 class="subsection-heading">Surviving Without Resistance</h2>
      <p class="subsection-desc">
        Treatment failure can begin with survival&mdash;not mutation. We study how susceptible pathogens persist <em>in vivo</em> under clinically grounded drug exposures.
      </p>

      <figure class="paper-figure">
        <Image src={rodriguesGA} alt="Graphical abstract showing experimental workflow: mouse model with barcoded E. coli, cefepime treatment, genomic analyses of 160 isolates, and in vitro phenotyping revealing persister and cell-invasion phenotypes" width={720} quality={95} densities={[1, 2]} />
        <figcaption>
          <strong>A clinically grounded model.</strong> A cefepime regimen tuned to human pharmacokinetics is applied to barcoded, patient-derived <em>E. coli</em> colonizing germ-free mice. Surviving lineages are sequenced and phenotyped to separate classical resistance from host-associated escape and persister-like survival.
        </figcaption>
      </figure>
      <figure class="paper-figure">
        <Image src={rodriguesFig3} alt="Lineage tracking of barcoded E. coli in untreated and cefepime-treated mice showing clonal dynamics, barcode diversity decline, and population bottlenecks" width={720} quality={95} densities={[1, 2]} />
        <figcaption>
          <strong>A bottleneck you can count.</strong> Under cefepime, barcode diversity collapses and a few clones dominate. This sharp within-host bottleneck emerges without increased MIC, implicating selection on survival strategies (e.g., invasion and persistence) rather than canonical resistance.
        </figcaption>
      </figure>

      <div class="article-card">
        <span class="article-card__label">Cell Host &amp; Microbe 2024</span>
        <h3 class="article-card__title">Susceptible bacteria can survive antibiotic treatment in the mammalian gastrointestinal tract without evolving resistance</h3>
        <p class="article-card__authors">Marinelle Rodrigues, Parastoo Sabaeifard, Muhammed Sadık Yıldız, Adam Lyon, Andrew Y. Koh, Erdal Toprak</p>
        <p class="article-card__journal"><em>Cell Host &amp; Microbe</em> (2024)</p>
        <p class="article-card__summary">
          In a mouse model that emulates human cefepime pharmacokinetics, a pansusceptible clinical <em>E. coli</em> strain disappears from stool yet remains recoverable from intestinal tissue. Survivors do not evolve higher MIC; instead, mutations increase epithelial invasion and/or enable persister-like survival, revealing a non-canonical route to treatment failure.
        </p>
        <div class="article-card__actions">
          <a href="https://doi.org/10.1016/j.chom.2024.01.010" target="_blank" rel="noopener noreferrer" class="article-card__btn">View Article</a>
        </div>
      </div>
    </div>
  </section>

  <section class="section">
    <div class="container">
      <h2 class="subsection-heading">Steering Evolution with Drug Design</h2>
      <p class="subsection-desc">
        Use molecular mechanism to turn evolution&rsquo;s favorite shortcut into a dead end.
      </p>

      <figure class="paper-figure">
        <Image src={mannaFig2} alt="Chemical structures of TMP and 4'-DTMP with dose-response curves showing 30-fold enhanced selective activity of 4'-DTMP against L28R DHFR mutants" width={720} quality={95} densities={[1, 2]} />
        <figcaption>
          <strong>Hitting the usual suspect.</strong> Trimethoprim resistance often begins with a single DHFR mutation (L28R). 4&rsquo;-DTMP retains potency against both wild-type DHFR and L28R, sharply reducing the advantage of that first step.
        </figcaption>
      </figure>
      <figure class="paper-figure">
        <Image src={mannaFig4} alt="Morbidostat IC50 trajectories comparing TMP and 4'-DTMP evolution rates, mutation frequency tracking, and evolutionary pathway Sankey diagrams" width={720} quality={95} densities={[1, 2]} />
        <figcaption>
          <strong>Rerouting trajectories in real time.</strong> In morbidostat evolutions, 4&rsquo;-DTMP suppresses the L28R route and slows the rise of resistance, diverting populations toward alternative DHFR solutions with higher fitness costs.
        </figcaption>
      </figure>

      <figure class="paper-figure">
        <video
          autoplay
          muted
          loop
          playsinline
          preload="metadata"
          width="720"
        >
          <source src="/videos/tamer-2019-dhfr-trajectories.mp4" type="video/mp4" />
        </video>
        <figcaption>
          <strong>Adaptive seascape of DHFR resistance.</strong> As trimethoprim concentration increases, the fitness landscape shifts — each pillar represents a DHFR allele, with height proportional to resistance (IC<sub>50</sub>). At low drug concentrations many evolutionary routes are viable, but as pressure intensifies only a few peaks remain, funneling populations toward predictable high-resistance genotypes.
          <span class="figure-source">Tamer, Gaszek, Abdizadeh et al., <em>MBE</em> (2019)</span>
        </figcaption>
      </figure>

      <div class="article-card">
        <span class="article-card__label">Nature Communications 2021</span>
        <h3 class="article-card__title">A trimethoprim derivative impedes antibiotic resistance evolution</h3>
        <p class="article-card__authors">Madhu Sudan Manna, Yusuf Talha Tamer, Ilona Gaszek et al.</p>
        <p class="article-card__journal"><em>Nature Communications</em> <strong>12</strong>, 3853 (2021)</p>
        <p class="article-card__summary">
          By dissecting the molecular logic of the canonical DHFR resistance mutation (L28R), we designed 4&rsquo;-DTMP&mdash;an inhibitor that stays potent against L28R. In evolution experiments, 4&rsquo;-DTMP selects against the usual shortcut and diverts populations to alternative DHFR mutations with catalytic penalties, slowing resistance emergence.
        </p>
        <div class="article-card__actions">
          <a href="https://www.nature.com/articles/s41467-021-23191-z" target="_blank" rel="noopener noreferrer" class="article-card__btn">View Article</a>
        </div>
      </div>
    </div>
  </section>

  <section class="section section--alt">
    <div class="container">
      <h2 class="subsection-heading">Deep Mutational Scanning</h2>
      <p class="subsection-desc">
        Combinatorially complete fitness landscapes reveal when resistance is predictable&mdash;and when it isn&rsquo;t.
      </p>

      <figure class="paper-figure">
        <Image src={gaszekFig1} alt="TEM-1 combinatorial mutant library design and fitness landscape under ampicillin and aztreonam selection" width={720} quality={95} densities={[1, 2]} />
        <figcaption>
          <strong>A complete map for TEM-1.</strong> We built all 55,296 TEM-1 &beta;-lactamase variants spanning 18 clinically observed mutations (13 residues) and measured fitness across drug environments, generating millions of empirical points on a resistance landscape.
        </figcaption>
      </figure>
      <figure class="paper-figure">
        <Image src={gaszekFig2} alt="Graph-theoretic fitness landscape showing neutral merging and fitness peaks" width={720} quality={95} densities={[1, 2]} />
        <figcaption>
          <strong>Why prediction breaks.</strong> Under a novel substrate (aztreonam), higher-order epistasis creates many accessible peaks and branching paths. Graph-based views make this ruggedness explicit&mdash;and quantify the inherent unpredictability it produces.
        </figcaption>
      </figure>

      <div class="article-card">
        <span class="article-card__label">Preprint 2025</span>
        <h3 class="article-card__title">Higher-order epistasis drives evolutionary unpredictability toward novel antibiotic resistance</h3>
        <p class="article-card__authors">Ilona K. Gaszek, Muhammed Sadık Yıldız et al.</p>
        <p class="article-card__journal"><em>bioRxiv</em> (2025)</p>
        <p class="article-card__summary">
          Ilona Gaszek and colleagues measured the largest resistance fitness landscape to date: <strong>55,296</strong> TEM-1 variants with <strong>&gt;8 million</strong> fitness measurements. Adaptation under a native substrate is comparatively smooth, while selection by a novel drug exposes extensive higher-order epistasis and ruggedness&mdash;the root of unpredictable evolutionary outcomes.
        </p>
        <div class="article-card__actions">
          <a href="https://www.biorxiv.org/content/10.1101/2025.07.08.663783v1.abstract" target="_blank" rel="noopener noreferrer" class="article-card__btn">View on bioRxiv</a>
        </div>
      </div>
    </div>
  </section>

  <section class="section">
    <div class="container">
      <h2 class="subsection-heading">Sequential Treatment Dynamics</h2>
      <p class="subsection-desc">
        The same drug can select for different solutions depending on what came before.
      </p>

      <figure class="paper-figure">
        <Image src={lyonFig1} alt="Evolution protocol scheme and survival outcomes during single antibiotic treatment" width={720} quality={95} densities={[1, 2]} />
        <figcaption>
          <strong>A clinically inspired evolution protocol.</strong> We evolve <em>E. coli</em> under high-dose killing while preserving population diversity, then transition cultures between antibiotics to test how history reshapes the path to sustained survival.
        </figcaption>
      </figure>
      <figure class="paper-figure">
        <Image src={lyonFig3} alt="Survival and phenotypic outcomes of sequential antibiotic treatment" width={720} quality={95} densities={[1, 2]} />
        <figcaption>
          <strong>History-dependent outcomes.</strong> Sequential therapy can shift evolutionary trajectories from divergent to convergent routes. Phenotypes may look similar, but the underlying mechanisms&mdash;resistance, tolerance, or persistence&mdash;and their genetic routes depend on treatment order.
        </figcaption>
      </figure>

      <div class="article-card">
        <span class="article-card__label">Preprint 2025</span>
        <h3 class="article-card__title">Context-dependent evolutionary dynamics toward bacterial survival during sequential antibiotic treatment</h3>
        <p class="article-card__authors">A. Lyon, M.S. Yıldız, E. Toprak</p>
        <p class="article-card__journal"><em>bioRxiv</em> (2025)</p>
        <p class="article-card__summary">
          Sequential antibiotic use can produce reproducible, history-dependent routes to survival. Our protocol exposes antibiotic-specific solutions (resistance, tolerance, persistence) and shows that treatment order can reshape collateral effects and the mutational paths that remain accessible.
        </p>
        <div class="article-card__actions">
          <a href="https://www.biorxiv.org/content/10.1101/2025.04.08.647880v2.abstract" target="_blank" rel="noopener noreferrer" class="article-card__btn">View on bioRxiv</a>
        </div>
      </div>

    </div>
  </section>

  <section class="section">
    <div class="container">
      <h2 class="subsection-heading">Related Publications</h2>
      <ul class="related-list">
        <li class="related-item">
          <a href="https://academic.oup.com/mbe/article/38/10/4493/6310175" target="_blank" rel="noopener noreferrer">
            <span class="related-item__title">The antibiotic efflux protein TolC is a highly evolvable target under colicin E1 and TLS phage selection</span>
            <span class="related-item__meta">Tamer, Gaszek, Rodrigues et al. &mdash; <em>MBE</em>, 2021</span>
          </a>
        </li>
        <li class="related-item">
          <a href="https://www.nature.com/articles/s42003-024-06750-0" target="_blank" rel="noopener noreferrer">
            <span class="related-item__title">Elucidating TolC protein dynamics: Structural shifts facilitate efflux mediated &beta;-lactam resistance</span>
            <span class="related-item__meta">Kantarcioglu, Gaszek, Guclu et al. &mdash; <em>Communications Biology</em>, 2024</span>
          </a>
        </li>
        <li class="related-item">
          <a href="https://academic.oup.com/mbe/article/36/7/1533/5458069" target="_blank" rel="noopener noreferrer">
            <span class="related-item__title">High-order epistasis in catalytic power of dihydrofolate reductase gives rise to a rugged fitness landscape in the presence of trimethoprim selection</span>
            <span class="related-item__meta">Tamer, Gaszek, Abdizadeh et al. &mdash; <em>MBE</em>, 2019</span>
          </a>
        </li>
        <li class="related-item">
          <a href="https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002552" target="_blank" rel="noopener noreferrer">
            <span class="related-item__title">Sequence-specific targeting of bacterial resistance genes increases antibiotic efficacy</span>
            <span class="related-item__meta">Ayhan, Tamer, Akbar et al. &mdash; <em>PLOS Biology</em>, 2016</span>
          </a>
        </li>
        <li class="related-item">
          <a href="https://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.1002299" target="_blank" rel="noopener noreferrer">
            <span class="related-item__title">Quantifying the determinants of evolutionary dynamics leading to drug resistance</span>
            <span class="related-item__meta">Chevereau, Dravecka, Batur et al. &mdash; <em>PLOS Biology</em>, 2015</span>
          </a>
        </li>
        <li class="related-item">
          <a href="https://www.nature.com/articles/ncomms8385" target="_blank" rel="noopener noreferrer">
            <span class="related-item__title">Delayed commitment to evolutionary fate in antibiotic resistance fitness landscapes</span>
            <span class="related-item__meta">Palmer*, Toprak*, Baym et al. &mdash; <em>Nature Communications</em>, 2015</span>
          </a>
        </li>
        <li class="related-item">
          <a href="https://academic.oup.com/mbe/article/31/9/2387/2925782" target="_blank" rel="noopener noreferrer">
            <span class="related-item__title">Strength of selection pressure is an important parameter contributing to the complexity of antibiotic resistance evolution</span>
            <span class="related-item__meta">Oz, Guvenek, de Yozgat et al. &mdash; <em>MBE</em>, 2014</span>
          </a>
        </li>
        <li class="related-item">
          <a href="https://www.nature.com/articles/ng.1034" target="_blank" rel="noopener noreferrer">
            <span class="related-item__title">Evolutionary paths to antibiotic resistance under dynamically sustained drug selection</span>
            <span class="related-item__meta">Toprak, Veres, Michel et al. &mdash; <em>Nature Genetics</em>, 2012</span>
          </a>
        </li>
      </ul>
    </div>
  </section>
</ScienceLayout>

<style>
  .section {
    padding-block: 1.25rem;
  }

  .vision-intro {
    max-width: 720px;
    margin-inline: auto;
    font-size: var(--size-md);
    line-height: 1.7;
  }

  .subsection-heading {
    font-family: var(--font-heading);
    font-size: var(--size-xl);
    font-weight: 400;
    text-transform: none;
    letter-spacing: normal;
    color: var(--color-gray-900);
    margin-bottom: 0.5rem;
    max-width: 720px;
    margin-inline: auto;
  }

  .subsection-desc {
    font-size: var(--size-sm);
    color: var(--color-gray-600);
    line-height: 1.6;
    max-width: 720px;
    margin-inline: auto;
    margin-bottom: 0.75rem;
  }

  .paper-figure {
    max-width: 720px;
    margin-inline: auto;
    border: 1px solid var(--color-gray-100);
    border-radius: 4px;
    overflow: hidden;
    margin-bottom: 1rem;
    background: var(--color-white);
  }

  .paper-figure:last-of-type {
    margin-bottom: 1.5rem;
  }

  .paper-figure img,
  .paper-figure video {
    width: 100%;
    height: auto;
    display: block;
  }

  .figure-source {
    display: block;
    margin-top: 0.375rem;
    font-size: var(--size-xs);
    color: var(--color-gray-300);
  }

  .paper-figure figcaption {
    padding: 0.625rem 1rem;
    font-size: var(--size-xs);
    color: var(--color-gray-600);
    line-height: 1.5;
    border-top: 1px solid var(--color-gray-100);
    background: var(--color-white);
  }

  .paper-figure figcaption strong {
    color: var(--color-gray-900);
  }

  .article-card {
    max-width: 720px;
    margin-inline: auto;
    border: 1px solid var(--color-gray-100);
    border-radius: 4px;
    padding: 1.75rem 2rem;
    background-color: var(--color-white);
  }

  .article-card__label {
    display: inline-block;
    font-family: var(--font-heading);
    font-size: var(--size-xs);
    font-weight: 600;
    text-transform: uppercase;
    letter-spacing: 0.08em;
    color: var(--color-navy-light);
    margin-bottom: 0.75rem;
  }

  .article-card__title {
    font-family: var(--font-heading);
    font-size: var(--size-lg);
    font-weight: 400;
    line-height: 1.4;
    margin-bottom: 1rem;
    color: var(--color-gray-900);
    text-transform: none;
    letter-spacing: normal;
  }

  .article-card__authors {
    font-size: var(--size-sm);
    color: var(--color-gray-600);
    margin-bottom: 0.25rem;
  }

  .article-card__journal {
    font-size: var(--size-sm);
    color: var(--color-gray-600);
    margin-bottom: 1rem;
  }

  .article-card__summary {
    font-size: var(--size-sm);
    line-height: 1.7;
    color: var(--color-gray-600);
    margin-bottom: 1.5rem;
    padding-top: 1rem;
    border-top: 1px solid var(--color-gray-100);
  }

  .article-card__actions {
    display: flex;
    gap: 1rem;
    flex-wrap: wrap;
  }

  .article-card__btn {
    display: inline-block;
    padding: 0.6rem 1.5rem;
    font-size: var(--size-sm);
    font-weight: 600;
    text-decoration: none;
    border: 1px solid var(--color-navy);
    color: var(--color-white);
    background-color: var(--color-navy);
    transition: background-color 0.2s, color 0.2s;
  }

  .article-card__btn:hover {
    background-color: var(--color-navy-light);
    border-color: var(--color-navy-light);
  }

  /* Related publications */
  .related-list {
    display: flex;
    flex-direction: column;
    gap: 0;
  }

  .related-item {
    border-left: 2px solid transparent;
    transition: border-color 0.2s;
  }

  .related-item:hover {
    border-left-color: var(--color-accent);
  }

  .related-item a {
    display: block;
    padding: 0.875rem 0 0.875rem 0.75rem;
    text-decoration: none;
    color: inherit;
    border-bottom: 1px solid var(--color-gray-100);
  }

  .related-item:last-child a {
    border-bottom: none;
  }

  .related-item__title {
    display: block;
    font-weight: 600;
    font-size: var(--size-sm);
    color: var(--color-gray-900);
    line-height: 1.5;
    margin-bottom: 0.25rem;
  }

  .related-item a:hover .related-item__title {
    color: var(--color-navy-light);
  }

  .related-item__meta {
    display: block;
    font-size: var(--size-xs);
    color: var(--color-gray-300);
  }

  @media (max-width: 768px) {
    .article-card {
      padding: 1.5rem;
    }
  }
</style>
